Andrew Sheldon - 9342-8530 Qubec Director
Director
Mr. Andrew J. Sheldon serves as an Independent Director of DiagnoCure Inc. Mr. Sheldon was President and Chief Executive Officer of Medicago Inc. a clinicalstage biopharmaceutical company since August 2003. He has thirty years of experience in the pharmaceutical industry and was named CEO of the Year by the Vaccine Industry Excellence awards at the World Vaccine Congress in April 2012. Before joining Medicago Mr. Sheldon was VicePresident Sales and Marketing of Shire Biologics where he was responsible for international expansion with European American and Asian private partnership agreements and was also responsible for distribution customer service maintenance and engineering at the Shire facility. From 1998 to 2000 he was Senior Manager of Commercial Operations where he managed the approval of a bladder cancer therapeutic vaccine by the FDA. In 1997 and 1998 he was Marketing Manager for Merial Canada Inc. From 1992 to 1997 he was Director of Canadian Operations with Rhne Mrieux. From 1988 to 1992 he was National Sales Manager for SmithKline Beecham since 2012.
| Tenure | 12 years |
| Phone | 418-527-6100 |
| Web | http://www.diagnocure.com |
9342-8530 Qubec Management Efficiency
The company has return on total asset (ROA) of 1.3432 % which means that it generated a profit of $1.3432 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2777 %, meaning that it generated $1.2777 on every $100 dollars invested by stockholders. 9342-8530 Qubec's management efficiency ratios could be used to measure how well 9342-8530 Qubec manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | DIRECTOR Age | ||
| Christopher Shackelton | Universal Technical Institute | 41 | |
| William Lennox | Universal Technical Institute | 71 | |
| David Blaszkiewicz | Universal Technical Institute | 52 | |
| Linda Srere | Universal Technical Institute | 65 | |
| Roderick Paige | Universal Technical Institute | 85 | |
| Kenneth Trammell | Universal Technical Institute | 60 | |
| John White | Universal Technical Institute | 70 | |
Management Performance
| Return On Equity | 1.28 | |||
| Return On Asset | 1.34 |
9342 8530 Qubec Leadership Team
Elected by the shareholders, the 9342-8530 Qubec's board of directors comprises two types of representatives: 9342-8530 Qubec inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 9342-8530. The board's role is to monitor 9342-8530 Qubec's management team and ensure that shareholders' interests are well served. 9342-8530 Qubec's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 9342-8530 Qubec's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yves Fradet, Non-Independent Chairman of the Board and Presidentident, Chief Medical Officer | ||
| Andrew Sheldon, Director | ||
| Pierre Dsy, Consulting Pres | ||
| Pierre Lapalme, Advisor Pres |
9342-8530 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 9342-8530 Qubec a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.28 | |||
| Return On Asset | 1.34 | |||
| Profit Margin | 0.41 % | |||
| Operating Margin | 0.77 % | |||
| Current Valuation | (392.06 K) | |||
| Shares Outstanding | 43.04 M | |||
| Price To Sales | 0 X | |||
| Revenue | 515.37 K | |||
| Gross Profit | 117.96 K | |||
| EBITDA | 5.46 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in 9342-8530 Stock
If you are still planning to invest in 9342 8530 Qubec check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the 9342-8530 Qubec's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |